Cincor Pharma (CINC)
US Market

Cincor Pharma (CINC) Stock Price & Analysis


CINC Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$10.53 - $43.15
Previous Close$28.79
Average Volume (3M)617.08K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-12.6
Next EarningsMar 21, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.29
Shares Outstanding43,764,323
Standard Deviation0.33
10 Day Avg. Volume1,367,584
30 Day Avg. Volume617,082
Price to Book (P/B)2.44
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-24.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside39.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Cincor Pharma’s price range in the past 12 months?
Cincor Pharma lowest stock price was $10.53 and its highest was $43.15 in the past 12 months.
    What is Cincor Pharma’s market cap?
    Currently, no data Available
    When is Cincor Pharma’s upcoming earnings report date?
    Cincor Pharma’s upcoming earnings report date is Mar 21, 2023 which is in 52 days.
      How were Cincor Pharma’s earnings last quarter?
      Cincor Pharma released its earnings results on Nov 03, 2022. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.609 by $0.099.
        Is Cincor Pharma overvalued?
        According to Wall Street analysts Cincor Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Cincor Pharma pay dividends?
          Cincor Pharma does not currently pay dividends.
          What is Cincor Pharma’s EPS estimate?
          Cincor Pharma’s EPS estimate is -$0.58.
            How many shares outstanding does Cincor Pharma have?
            Cincor Pharma has 43,764,324 shares outstanding.
              What happened to Cincor Pharma’s price movement after its last earnings report?
              Cincor Pharma reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.609. Following the earnings report the stock price went down -14.299%.
                Which hedge fund is a major shareholder of Cincor Pharma?
                Among the largest hedge funds holding Cincor Pharma’s share is Perceptive Advisors LLC. It holds Cincor Pharma’s shares valued at 109M.


                  Cincor Pharma Stock Smart Score

                  The Cincor Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Cincor Pharma

                  CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  SIGA Technologies
                  Cara Therapeutics
                  Edgewise Therapeutics
                  Nektar Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis